Sunday , 23 February 2025
Home Health Impact of genericization on drug prices and treatment value across 8 countries
Health

Impact of genericization on drug prices and treatment value across 8 countries

Impact of genericization on drug prices and treatment value across 8 countries

An interesting study from Miquel Serra-Burriel et al. (2024) examines the impact of genericization on drug prices across 8 high-income countries (Australia, Canada, France, Germany, Japan, Switzerland, UK, and US). The authors used 2011-2020 IQVIA MIDAS data across 505 novel originator drugs. They found that:

Price decreases were statistically significant over the 8 years after patent expiration, with the fastest price declines observed in the US: 32% (95% CI, 24%-39%) in year 1 after patent expiration and 82% (95% CI, 71%-89%) in the 8 years after patent expiration. Estimates for other nations ranged from a decrease of 64% in Australia to 18% in Switzerland in the 8 years after expiration. The cost-effectiveness simulation model indicated that not accounting for generic entry into the market may produce biased incremental cost-effectiveness ratios of 40% to −40%, depending on the scenario.

https://jamanetwork.com/journals/jama-health-forum/fullarticle/2822169

You can read the full article here.

Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Articles

A paper by Proudman et al. (2024) finds that doing so would...

Carlyle and SK Capital Partners are buying beleaguered gene therapy biotech Bluebird...

Hospitals are adopting AI technology more than ever before, but they still...

This fact sheet provides an overview of the history of the Kemp-Kasten...